基于初始治疗反应预测新生血管性年龄相关性黄斑变性的长期视力结局
该研究基于Fight Retinal Blindness!登记数据库,纳入2051只接受抗VEGF治疗且前3个月完成3次注射的初治眼,探索多种早期反应指标与3年视力结局的关联。结果显示第四次注射时达到良好视力(≥70字母)与3年视力结局强相关,其他早期反应指标呈中度关联,初始3个月早期反应可指导后续治疗决策。
要点
- 第四次注射时视力≥70字母与3年达到良好视力强相关(OR 9.8,95%CI 6.5-14.7)。
- 早期视力小增益(1-5字母)或大增益(>5字母)均与3年良好视力相关,优于早期视力下降。
- 首次病灶无活动性分级所需注射次数≤3次与3年良好视力相关(OR 1.6,95%CI 1.2-2.1)。
核心结论
- 第四次注射时达到良好视力与3年视力结局强相关,其他早期反应指标呈中度关联。
- 初始3个月注射期间的早期反应可作为后续治疗决策的有用参考。
研究设计与样本
- 前瞻性设计的数据库研究,数据来自Fight Retinal Blindness!登记库。
- 纳入2007年1月1日至2014年3月1日期间开始抗VEGF治疗且前3个月内接受3次注射的初治眼,共2051只眼(1828例患者)。
主要发现
- 第四次注射时视力≥70字母 vs <70字母,3年达到良好视力的OR为9.8(95%CI 6.5-14.7)。
- 早期视力小增益(1-5字母)vs 早期视力下降,OR为1.8(95%CI 1.2-2.6,P=0.002);大增益(>5字母)vs 早期视力下降,OR为1.8(95%CI 1.3-2.5,P<0.001)。
- 首次病灶无活动性分级所需注射次数≤3次 vs >3次,OR为1.6(95%CI 1.2-2.1,P<0.001)。
- 相邻注射间视力渐变(-4至4字母)vs 快速下降,OR为1.7(95%CI 1.1-2.6,P=0.015);快速增益(≥5字母)vs 快速下降,OR为1.6(95%CI 1.1-2.3,P=0.018)。
- 早期视力小增益和大增益眼3年视力相似(分别为65.0和64.7字母),均优于早期视力下降眼(57.2字母)。
关键数值与推荐
- 早期反应定义为至第四次注射期间的表现。
- 良好视力定义为视力≥70字母(Snellen等效20/40)。
- 主要结局指标为3年时达到≥70字母的眼比例。
临床怎么用
- 第四次注射时的视力水平可强烈预测3年视力结局,应重视该时间点的评估。
- 初始3个月注射期间的早期反应(视力变化、病灶无活动性分级时间、注射间视力变化速率)可辅助后续治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore various methods for assessing the early response to vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration and investigate their association with 3-year visual acuity (VA) outcomes. DESIGN: Database study, prospectively designed. PARTICIPANTS: Treatment-naïve eyes in the Fight Retinal Blindness! registry that commenced anti-VEGF therapy between January 1, 2007, and March 1, 2014, that received 3 anti-VEGF injections within the first 3 months. METHODS: The early response was defined as occurring up until the fourth injection. Various early response metrics were explored: (1) achieving good VA (≥70 letters; Snellen equivalent, 20/40), (2) absolute change in VA from baseline, (3) time to first grading of the choroidal neovascular lesion as inactive, and (4) maximum rate of VA change between successive injections. MAIN OUTCOME MEASURES: Proportion of eyes achieving ≥70 letters 3 years. RESULTS: This study included 2051 treatment-naïve eyes from 1828 patients. Achieving good vision at 3 years was associated significantly with (1) having good vision by the fourth injection (VA ≥70 vs. VA <70 letters: odds ratio [OR], 9.8; 95% confidence interval [CI], 6.5-14.7), (2) small (1-5 letters) or large (>5 letters) early VA gains (vs. early VA loss: OR, 1.8; 95% CI, 1.2-2.6; P = 0.002; and OR, 1.8; 95% CI, 1.3-2.5; P < 0.001), (3) fewer injections until first grading of lesion inactivity (≤3 vs. >3 injections: OR, 1.6; 95% CI, 1.2-2.1; P < 0.001), (4) gradual change (between -4 and 4 letters) or rapid gains (≥5 letters) between successive injections (vs. rapid loss: OR, 1.7; 95% CI, 1.1-2.6; P = 0.015; and OR, 1.6; 95% CI, 1.1-2.3; P = 0.018). Eyes that achieved small or large early gains had similar vision at 3 years (65.0 and 64.7 letters, respectively) and had better vision than eyes with early VA loss (57.2 letters). CONCLUSIONS: Attainment of good vision by the fourth injection was associated strongly with 3-year visual outcomes, whereas other early response parameters showed a moderate association. The early response during the initial 3 monthly injections can be a useful guide for subsequent treatment decisions.
引用
- Nguyen V, Daien V, Guymer R, et al. Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018. PMID: 30149035. doi:10.1016/j.ophtha.2018.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。